Pregnancy co-treated with oral gonadotropin-releasing hormone antagonist in a woman with premature ovarian insufficiency: a case report.

IF 0.9 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Daichi Inoue, Manami Kondo, Rie Mizuno, Shinichi Shibuya, Yoshiki Hashiba, Yoshimasa Asada
{"title":"Pregnancy co-treated with oral gonadotropin-releasing hormone antagonist in a woman with premature ovarian insufficiency: a case report.","authors":"Daichi Inoue, Manami Kondo, Rie Mizuno, Shinichi Shibuya, Yoshiki Hashiba, Yoshimasa Asada","doi":"10.18999/nagjms.86.2.333","DOIUrl":null,"url":null,"abstract":"<p><p>To the best of our knowledge, this is the first case of pregnancy with a healthy baby after treatment with an oral gonadotropin-releasing hormone (GnRH) antagonist in women with premature ovarian insufficiency. A 36-year-old female presented at our hospital after being diagnosed with premature ovarian insufficiency by a previous doctor. We administered clomiphene, human menopausal gonadotropin (hMG), and GnRH antagonist (injection) together with estrogen replacement for 11 cycles (27 months), but no follicular development was observed. When the oral GnRH antagonist (relugolix), which has recently become available, was used in the 12<sup>th</sup> cycle, follicular growth of 13 mm was confirmed on the 14<sup>th</sup> day of stimulation. After stimulation, the use of hMG and GnRH antagonist (injection) was continued, and a maturation trigger, human chorionic gonadotropin 10000 IU, was administered. Oocyte retrieval was performed successfully, intracytoplasmic sperm injection and frozen embryo transfer were performed, and fetal heartbeat was confirmed. The patient was admitted to the perinatal management facility. She delivered a healthy baby of 3,732 g via cesarean section at 41 weeks +2. This case shows the possibility of using an oral GnRH antagonist as an option for infertility treatment.</p>","PeriodicalId":49014,"journal":{"name":"Nagoya Journal of Medical Science","volume":"86 2","pages":"333-340"},"PeriodicalIF":0.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219225/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nagoya Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18999/nagjms.86.2.333","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

To the best of our knowledge, this is the first case of pregnancy with a healthy baby after treatment with an oral gonadotropin-releasing hormone (GnRH) antagonist in women with premature ovarian insufficiency. A 36-year-old female presented at our hospital after being diagnosed with premature ovarian insufficiency by a previous doctor. We administered clomiphene, human menopausal gonadotropin (hMG), and GnRH antagonist (injection) together with estrogen replacement for 11 cycles (27 months), but no follicular development was observed. When the oral GnRH antagonist (relugolix), which has recently become available, was used in the 12th cycle, follicular growth of 13 mm was confirmed on the 14th day of stimulation. After stimulation, the use of hMG and GnRH antagonist (injection) was continued, and a maturation trigger, human chorionic gonadotropin 10000 IU, was administered. Oocyte retrieval was performed successfully, intracytoplasmic sperm injection and frozen embryo transfer were performed, and fetal heartbeat was confirmed. The patient was admitted to the perinatal management facility. She delivered a healthy baby of 3,732 g via cesarean section at 41 weeks +2. This case shows the possibility of using an oral GnRH antagonist as an option for infertility treatment.

一名卵巢早衰妇女在口服促性腺激素释放激素拮抗剂的同时怀孕:病例报告。
据我们所知,这是第一例卵巢早衰患者在口服促性腺激素释放激素(GnRH)拮抗剂治疗后怀孕并生下健康婴儿的病例。一名 36 岁的女性被之前的医生诊断为卵巢早衰,随后来到我院就诊。我们给她注射了克罗米芬、人绝经促性腺激素(hMG)和 GnRH 拮抗剂(注射剂),并用雌激素替代了 11 个周期(27 个月),但未观察到卵泡发育。在第 12 个周期使用最近上市的口服 GnRH 拮抗剂(relugolix)时,在刺激的第 14 天确认卵泡生长了 13 毫米。刺激后,继续使用 hMG 和 GnRH 拮抗剂(注射),并注射了成熟触发剂--人绒毛膜促性腺激素 10000 IU。取卵成功,进行了卵胞浆内单精子注射和冷冻胚胎移植,并确认了胎心搏动。患者被送入围产期管理机构。她在 41+2 周时通过剖腹产顺利产下一名重 3 732 克的健康婴儿。本病例显示了使用口服 GnRH 拮抗剂治疗不孕症的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nagoya Journal of Medical Science
Nagoya Journal of Medical Science MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
1.30
自引率
0.00%
发文量
65
审稿时长
>12 weeks
期刊介绍: The Journal publishes original papers in the areas of medical science and its related fields. Reviews, symposium reports, short communications, notes, case reports, hypothesis papers, medical image at a glance, video and announcements are also accepted. Manuscripts should be in English. It is recommended that an English check of the manuscript by a competent and knowledgeable native speaker be completed before submission.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信